Apellis Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Apellis Pharmaceuticals
APLS Stock  USD 17.64  0.12  0.68%   
Apellis Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apellis Pharmaceuticals' valuation are provided below:
Gross Profit
314.7 M
Profit Margin
(0.29)
Market Capitalization
2.2 B
Enterprise Value Revenue
3.0203
Revenue
775.8 M
There are over one hundred nineteen available fundamental signals for Apellis Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Apellis Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 1.8 B in 2025. Enterprise Value is likely to gain to about 1.6 B in 2025

Apellis Pharmaceuticals Total Revenue

820.44 Million

Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 42.4 M or Selling General Administrative of 526.1 M, as well as many indicators such as Price To Sales Ratio of 4.81, Dividend Yield of 0.0 or PTB Ratio of 18.84. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Apellis Stock
Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Apellis Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets470.8 M885.1 M351.4 M
Slightly volatile
Other Current Liabilities147.2 M140.2 M56.6 M
Slightly volatile
Total Current Liabilities194.8 M185.5 M72.2 M
Slightly volatile
Total Stockholder Equity129.9 M228.5 M97.5 M
Slightly volatile
Property Plant And Equipment Net16.2 M19 M9.5 M
Slightly volatile
Accounts Payable40.5 M38.6 M13 M
Slightly volatile
Cash302.8 M411.3 M226.3 M
Slightly volatile
Non Current Assets Total100.9 M96.1 M23.7 M
Slightly volatile
Cash And Short Term Investments337 M411.3 M251.8 M
Slightly volatile
Net Receivables285.3 M271.7 M52.4 M
Slightly volatile
Common Stock Total Equity9.7 K9.2 K4.7 K
Slightly volatile
Common Stock Shares Outstanding65.2 M123.9 M51.9 M
Slightly volatile
Liabilities And Stockholders Equity470.8 M885.1 M351.4 M
Slightly volatile
Inventory51.9 M81.4 M23.9 M
Slightly volatile
Other Current Assets29.7 M24.5 M22.2 M
Slightly volatile
Other Stockholder Equity3.4 B3.3 B1 B
Slightly volatile
Total Liabilities341 M656.5 M253.9 M
Slightly volatile
Property Plant And Equipment Gross18.1 M19 M13.3 M
Slightly volatile
Total Current Assets445.4 M789 M332.5 M
Slightly volatile
Common Stock14.5 K13.8 K5.8 K
Slightly volatile
Other Assets19.1 M18.2 M7.5 M
Slightly volatile
Property Plant Equipment16.9 M28.6 M10.4 M
Slightly volatile
Capital Surpluse743.6 M708.2 M341.9 M
Slightly volatile
Preferred Stock Total Equity93.1 M105.9 M87.4 M
Slightly volatile
Short and Long Term Debt Total493.3 M469.8 M148.8 M
Slightly volatile
Other Liabilities192.4 M363 M120.2 M
Slightly volatile
Long Term Debt475.5 M452.8 M127.6 M
Slightly volatile
Long Term Debt Total172.1 M164 M80.3 M
Slightly volatile
Net Invested Capital374.4 M681.4 M270.3 M
Slightly volatile
Short and Long Term Debt1.4 M1.5 M14 M
Slightly volatile
Net Working Capital525.7 M603.4 M348.6 M
Slightly volatile
Short Term Debt6 M6.8 M15.7 M
Slightly volatile
Capital Stock10.2 K13.8 K7.6 K
Slightly volatile
Capital Lease Obligations20.1 M17 M16.2 M
Slightly volatile
Current Deferred Revenue86.1 M92.9 M107.5 M
Slightly volatile
Short Term Investments952.5 K1 M218.8 M
Slightly volatile
Non Current Liabilities Other7.6 M8 M294.7 M
Slightly volatile

Apellis Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.7 M1.8 M13.6 M
Very volatile
Selling General Administrative526.1 M501.1 M140.1 M
Slightly volatile
Other Operating Expenses993.7 M946.3 M320.8 M
Slightly volatile
Research Development202 M327.6 M150.8 M
Slightly volatile
Total Operating Expenses870.1 M828.6 M299.8 M
Slightly volatile
Non Recurring21.2 M23.8 M26 M
Slightly volatile
Interest Income7.6 M12.8 M4.1 M
Slightly volatile
Reconciled Depreciation1.2 M1.8 M553.1 K
Slightly volatile
Tax Provision1.4 M1.2 M1.6 M
Slightly volatile
Selling And Marketing Expenses1.4 M1.5 M1.7 M
Slightly volatile

Apellis Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation119.8 M114.1 M36.5 M
Slightly volatile
Begin Period Cash Flow265.7 M352.3 M197.9 M
Slightly volatile
Depreciation1.9 M1.8 M611.2 K
Slightly volatile
Other Non Cash Items14.1 M12.4 M10.5 M
Slightly volatile
Total Cash From Financing Activities256.1 M149.2 M192 M
Slightly volatile
End Period Cash Flow303.4 M412.6 M226.7 M
Slightly volatile
Net Borrowings389.9 M371.3 M164.5 M
Slightly volatile
Change To Netincome183.7 M174.9 M73 M
Slightly volatile
Dividends Paid258.3 M290.6 M316.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.815.060121.8239
Pretty Stable
PTB Ratio18.8417.300429.3657
Slightly volatile
Days Sales Outstanding71.3812755.0979
Slightly volatile
Book Value Per Share1.911.84451.956
Pretty Stable
Average Payables3.4 M6.3 M4.5 M
Slightly volatile
Stock Based Compensation To Revenue0.140.14610.3009
Slightly volatile
Capex To Depreciation0.210.22433.8508
Slightly volatile
PB Ratio18.8417.300429.3657
Slightly volatile
EV To Sales4.885.13520.5117
Pretty Stable
Inventory Turnover1.521.44620.4539
Slightly volatile
Days Of Inventory On Hand2402521.3 K
Very volatile
Payables Turnover2.93.05210.5447
Slightly volatile
Sales General And Administrative To Revenue1.631.141.0301
Slightly volatile
Average Inventory192 K216 K235.5 K
Slightly volatile
Research And Ddevelopement To Revenue0.40.41921.6458
Pretty Stable
Capex To Revenue5.0E-45.0E-40.0174
Slightly volatile
Cash Per Share3.833.31943.8802
Slightly volatile
Days Payables Outstanding114120278
Slightly volatile
Income Quality0.860.4440.8023
Pretty Stable
Current Ratio4.044.25298.6042
Slightly volatile
Tangible Book Value Per Share1.911.84451.956
Pretty Stable
Receivables Turnover2.732.87568.385
Slightly volatile
Shareholders Equity Per Share1.911.84451.956
Pretty Stable
Debt To Equity1.112.05560.8423
Slightly volatile
Capex Per Share0.00310.00330.0159
Pretty Stable
Revenue Per Share6.626.30623.4031
Pretty Stable
Interest Debt Per Share4.324.11752.3431
Slightly volatile
Debt To Assets0.560.53080.2317
Slightly volatile
Operating Cycle360379564
Slightly volatile
Price Book Value Ratio18.8417.300429.3657
Slightly volatile
Days Of Payables Outstanding114120278
Slightly volatile
Ebt Per Ebit0.891.19241.0732
Slightly volatile
Company Equity Multiplier2.663.87262.8738
Slightly volatile
Long Term Debt To Capitalization0.350.66460.3102
Slightly volatile
Total Debt To Capitalization0.370.67270.321
Slightly volatile
Debt Equity Ratio1.112.05560.8423
Slightly volatile
Quick Ratio3.623.81418.3393
Slightly volatile
Net Income Per E B T0.81.00590.9815
Very volatile
Cash Ratio2.112.21717.4753
Slightly volatile
Days Of Inventory Outstanding2402521.3 K
Very volatile
Days Of Sales Outstanding71.3812755.0979
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00461.0128
Slightly volatile
Price To Book Ratio18.8417.300429.3657
Slightly volatile
Fixed Asset Turnover43.141.04913.8106
Slightly volatile
Debt Ratio0.560.53080.2317
Slightly volatile
Price Sales Ratio4.815.060121.8239
Pretty Stable
Asset Turnover0.930.88280.335
Slightly volatile
Gross Profit Margin0.980.84930.9018
Very volatile
Price Fair Value18.8417.300429.3657
Slightly volatile

Apellis Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.1 B
Slightly volatile
Enterprise Value1.6 B1.5 B953.4 M
Slightly volatile

Apellis Fundamental Market Drivers

Cash And Short Term Investments411.3 M

Apellis Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue92.9 M86.1 M
Total Revenue781.4 M820.4 M
Cost Of Revenue117.7 M67.9 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue 1.14  1.63 
Research And Ddevelopement To Revenue 0.42  0.40 
Revenue Per Share 6.31  6.62 
Ebit Per Revenue(0.21)(0.22)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY